

CURRICULUM VITAE

Ranjala Ratnayake

Contact:

Research Assistant Professor
Assistant Director, Center for Natural Products, Drug Discovery and Development (CNP3)
University of Florida
Department of Medicinal Chemistry
1345 Center Drive, P5-27
P.O. Box 100485
Gainesville, FL 32610

Office: (352) 627-9220

Email: rratnayake@cop.ufl.edu

Center: <https://cnpd3.pharmacy.ufl.edu/>

EDUCATION

2009 – 2011	Postdoctoral Associate (Advisor – Prof. Hendrik Luesch)	University of Florida/USA	Chemical Biology
2007 – 2009	Postdoctoral Fellow (Advisors – Drs. John A. Beutler & Kirk R. Gustafson)	National Institutes of Health, NCI/USA	Chemical Biology
2006 – 2007	Postdoctoral Fellow (Advisor – Prof. Robert J. Capon)	University of Queensland, IMB/Australia	Chemistry
2002 – 2006	PhD (Advisor – Prof. Robert J. Capon)	University of Queensland, IMB/Australia	Chemistry
1997 – 2000	MPhil (Advisor – Kamal B. Gunaherath)	The Open University of Sri Lanka	Chemistry
1992 – 1996	BSc (Advisor – Kamal B. Gunaherath)	The Open University of Sri Lanka	Chemistry/Biology

APPOINTMENTS

2016 -	Research Assistant Professor , University of Florida, Department of Medicinal Chemistry Assistant Director , Center for Natural Products, Drug Discovery and Development (CNP3) Research Core Leader , Molecular Diversity and Screening Core at CNPD3
2014 – 2016	Assistant Scientist , University of Florida, Department of Medicinal Chemistry, USA
2012 – 2013	Head of Research (R&D) , Plant Research Centre, Nature's Beauty Creations Ltd., Sri Lanka
2002 – 2006	Research Assistant , Institute for Molecular Biosciences, University of Queensland, Australia
2001 – 2002	QC Chemist , A. Baur & Company. Limited, Sri Lanka
2000 – 2001	Research Assistant , Department of Chemistry, Sri Jayewardenepura University, Sri Lanka
1997 – 2000	Research Assistant , Department of Chemistry, Open University of Sri Lanka, Sri Lanka
1992 – 1997	School Teacher , S. Thomas' College, Sri Lanka

PROFESSIONAL EXPERIENCE

2009	Good Manufacturing Practice (GMP) regulations (21 CFR 210, 211) Biopharmaceutical Development Program, SAIC-Frederick, Inc., USA
2009	Research Management NCI, Frederick MD, USA
2005	Commercialization of Science, IMBcom Pty Ltd, Australia
2001	Laboratory Quality Management, Institute of Chemistry Ceylon, Sri Lanka
2001	Laboratory Accreditation, Sri Lanka Standards Institution

RESEARCH INTERESTS

Drug Discovery and Development; marine and microbial natural products, isolation and structure determination of natural products, NMR and Mass Spectroscopy, high-throughput screening, high-content imaging, assay development and assay miniaturization for drug library and siRNA screening, mechanisms of action, cancer and infectious disease.

RESEARCH FUNDING

1R50CA211487-01 (NIH/NCI Research Specialist Award) – (Role: PI Ratnayake)/9.0 CM
 “Development of Complex Natural Product Libraries and multidimensional anticancer screening platforms.”
 09/20/16 – 08/31/2021; Total costs \$465,481.00 (Direct costs, \$310,320.00); no cost extension 08-31-2022

131947-RSG-18-013-01-CDD (American Cancer Society) – (PI-Huigens; Role: Co-Investigator, Ratnayake)/0.6 CM
 “Alkaloid Ring Distortion: A Platform for New Cancer Therapies.”
 07/01/2018 – 6/30/2022; Total costs \$792,000.00 (Direct costs, \$660,000.00)

UF Health Cancer Center (UFHCC), Davis Cancer Research grant – (Role: PI Ratnayake)/1.8 CM
 09/20/2016 – 08/31/2021; Award Amount \$504,555.92

HONORS & AWARDS

- 2019 Scientific Presentation Award, International Conference on Pharmacology, Singapore
- 2016 NIH/NCI Research Specialist Award (R50 grant), USA
- 2009 Active Member Travel Award - American Society of Pharmacognosy, USA
- 2007 PhD Dissertation, Deans Commendation List, University of Queensland, Australia, *Recognition for outstanding quality and exceptionally innovative nature of the research*
- 2006 Student Research Award - American Society of Pharmacognosy, USA- *Recognition for outstanding research in the general area of Natural Products*
- 2005 Lynn Brady Travel Award - American Society of Pharmacognosy, USA
- 2005 Graduate School Research Travel Award (GSRTA) - University of Queensland, Australia
- 2003 Graduate School Research Scholarship (GSRS) Award - University of Queensland, Australia
- 2002 Melbourne International Research Scholarship (MIRS) Award - University of Melbourne, Australia
- 2002 International Postgraduate Research Scholarship (IPRS) - Australian Government
- 2001 Kandiah Memorial Award I - Institute of Chemistry Ceylon, Sri Lanka- *For the best Postgraduate Research in Chemistry, carried out at a Higher Educational Institution in Sri Lanka.*

INSTITUTIONAL AFFILIATIONS/PROFESSIONAL SOCIETIES

- 2016 – UF Health Cancer Center (UFHCC)
- 2009 – Member, American Society of Pharmacognosy (ASP)
- 2002 – Member and Chartered Chemist (C. Chem.), Institute of Chemistry Ceylon (Sri Lanka)
- 1999 – Member, Sri Lanka Association for the Advancement of Science (SLAAS)

PUBLICATIONS IN REFEREED JOURNALS (41)

1. Gunasekera, S. P.; Kokkaliari, S.; **Ratnayake, R.**; Sauvage, T.; dos Santos, L. A. H.; Luesch, H.; Paul, V. J. “Anti-inflammatory Dysidazirine Carboxylic Acid from the Marine Cyanobacterium *Caldora* sp. Collected from the Reefs of Fort Lauderdale, Florida” *Molecules* 2022, 27, 1717
2. Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm. Cai W, Ratnayake R (co-1st author), Wang M, Chen QY, Raisch KP, Dang LH, Law BK, Luesch H. *Curr Res Pharmacol Drug Disc.* 2021 Sep 8;2: 100053
3. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site. Matthew S, Chen QY, **Ratnayake R**, Fermaintt CS, Lucena-Agell D, Bonato F, Prota AE, Lim ST, Wang X, Díaz JF, Risinger AL, Paul VJ, Oliva MÁ, Luesch H. *Proc Natl Acad Sci U S A.* 2021 Mar 2;118(9):e2021847118.
4. Function-Oriented and Modular (+/-)-cis-Pseudoguaianolide Synthesis: Discovery of New Nrf2 Activators and NF-κB Inhibitors. Emmetiere F, **Ratnayake R**, Schares HAM, Jones KFM, Bevan-Smith E, Luesch H, Harki DA, Grenning AJ. *Chemistry.* 2021 Mar 22;27(17):5564-5571
5. Vicinal difluorination as a C=C surrogate: an analog of piperine with enhanced solubility, photostability, and acetylcholinesterase inhibitory activity. Lizarme-Salas Y, Ariawan AD, **Ratnayake R**, Luesch H, Finch A, Hunter L. *Beilstein J Org Chem.* 2020 Oct 28;16:2663-2670.
6. Fungal epithiodiketopiperazines carrying α, β-polysulfide bridges from *Penicillium steckii* YE, and their chemical interconversion. Jiang G, Zhang P, **Ratnayake R**, Yang G, Zhang Y, Zuo R, Powell M, Huguet-Tapia JC, Abboud KA, Dang LH, Teplitski M, Paul V, Xiao R, Zaman KAU, Hu Z, Cao S, Luesch H, Ding Y. *Chembiochem.* 2021 Jan 15;22(2):416-422.
7. Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed

- Activities against Cancer-Relevant GPCR Targets. Paciaroni NG, Norwood VM 4th, **Ratnayake R**, Luesch H, Huigens RW 3rd. *Bioorg Med Chem*. 2020 Jul 15;28(14):115546.
8. Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases. Al-Awadhi FH, Salvador-Reyes LA, Elsadek LA, **Ratnayake R**, Chen QY, Luesch H. *ACS Chem Neurosci*. 2020 Jul 1;11(13):1937-1943.
 9. High-throughput gene screen reveals modulators of nuclear shape. Tamashunas AC, Tocco VJ, Matthews J, Zhang Q, Atanasova KR, Paschall L, Pathak S, **Ratnayake R**, Stephens AD, Luesch H, Licht JD, Lele TP. *Mol Biol Cell*. 2020 Jun 15;31(13):1392-1402.
 10. Dolastatin 15 from a Marine Cyanobacterium Suppresses HIF-1 α Mediated Cancer Cell Viability and Vascularization. **Ratnayake R**, Gunasekera SP, Ma JJ, Dang LH, Carney TJ, Paul VJ, Luesch H. *Chembiochem*. 2020 Aug 17;21(16):2356-2366.
 11. Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity. Norwood VM 4th, Brice-Tutt AC, Eans SO, Stacy HM, Shi G, **Ratnayake R**, Rocca JR, Abboud KA, Li C, Luesch H, McLaughlin JP, Huigens RW 3rd. *J Med Chem*. 2020 May 28;63(10):5119-5138.
 12. A tetrapeptide class of biased analgesics from an Australian fungus targets the μ -opioid receptor. Dekan Z, Sianati S, Yousuf A, Sutcliffe KJ, Gillis A, Mallet C, Singh P, Jin AH, Wang AM, Mohammadi SA, Stewart M, **Ratnayake R**, Fontaine F, Lacey E, Piggott AM, Du YP, Canals M, Sessions RB, Kelly E, Capon RJ, Alewood PF and MacDonald JC. *Proc Natl Acad Sci USA* first published October 14, 2019
 13. Seaweed natural products modify the host inflammatory response via Nrf2 signaling and alter colon microbiota composition and gene expression. Bousquet MS, **Ratnayake R**, Pope JL, Chen QY, Zhu F, Chen S, Carney TJ, Gharaibeh RZ, Jobin C, Paul VJ, Luesch H. *Free Radic Biol Med*. 2019 Sep 16. pii: S0891-5849(19)30996-7. doi: 10.1016/j.freeradbiomed.2019.09.013. [Epub ahead of print]
 14. Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model. Cai W, **Ratnayake R**, Gerber MH, Chen QY, Yu Y, Derendorf H, Trevino JG, Luesch H. *Invest New Drugs*. 2019 Apr;37(2):364-374
 15. Total Synthesis of Asperphenins A and B. Yan JL, Cheng Y, Chen J, **Ratnayake R**, Dang LH, Luesch H, Guo Y, Ye T. *Org Lett*. 2018 Oct 5;20(19):6170-6173
 16. Apratyramide, a Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing. Cai W, Salvador-Reyes LA, Zhang W, Chen QY, Matthew S, **Ratnayake R**, Seo SJ, Dolles S, Gibson DJ, Paul VJ, Luesch H. *ACS Chem Biol*. 2018 Jan 19;13(1):91-99
 17. Synthesis and biological evaluation of largazole zinc-binding group analogs. Kim B, **Ratnayake R**, Lee H, Shi G, Zeller SL, Li C, Luesch H, Hong J. *Bioorg Med Chem*. 2017 Jun 15;25(12):3077-3086
 18. A Tryptoline Ring-Distortion Strategy Leads to Complex and Diverse Biologically Active Molecules from the Indole Alkaloid Yohimbine. Paciaroni NG, **Ratnayake R**, Matthews JH, Norwood VM 4th, Arnold AC, Dang LH, Luesch H, Huigens RW 3rd. *Chemistry*. 2017 Mar 28;23(18):4327-4335
 19. Caldoramide, a Modified Pentapeptide from the Marine Cyanobacterium *Caldora penicillata*. Gunasekera SP, Imperial L, Garst C, **Ratnayake R**, Dang LH, Paul VJ, Luesch H. *J Nat Prod*. 2016, 79(7):1867-71.
 20. Tasiamide F, a potent inhibitor of cathepsins D and E from a marine cyanobacterium. Al-Awadhi FH, **Ratnayake R**, Paul VJ, Luesch H. *Bioorg Med Chem*. 2016;24(15):3276-82.
 21. Discovery, Total Synthesis and Key Structural Elements for the Immunosuppressive Activity of Cocosolide, a Symmetrical Glycosylated Macrolide Dimer from Marine Cyanobacteria. Gunasekera SP, Li Y, **Ratnayake R**, Luo D, Lo J, Reibenspies JH, Xu Z, Clare-Salzler MJ, Ye T, Paul VJ, Luesch H. *Chemistry*. 2016, 22(24):8158-66.
 22. Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells. Caropreso V, Darvishi E, Turbyville TJ, **Ratnayake R**, Grohar PJ, McMahon JB, Woldemichael GM. *J Biol Chem*. 2016, 6;291(19):10058-66.
 23. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer. Bousquet MS, Ma JJ, **Ratnayake R**, Havre PA, Yao J, Dang NH, Paul VJ, Carney TJ, Dang LH, Luesch H. *ACS Chem Biol*. 2016, 11(5):1322-31
 24. C3 and 2D C3 Marfey's Methods for Amino Acid Analysis in Natural Products. Vijayarathay S, Prasad P, Fremlin LJ, **Ratnayake R**, Salim AA, Khalil Z, Capon RJ. *J Nat Prod*. 2016, 79(2):421-7.
 25. Grassypeptolides as natural inhibitors of dipeptidyl peptidase 8 and T-cell activation. Kwan JC, Liu Y, **Ratnayake R**, Hatano R, Kuribara A, Morimoto C, Ohnuma K, Paul VJ, Ye T, Luesch H. *Chembiochem*.

- 2014, 15(6):799-804.
26. Cultivated sea lettuce is a multiorgan protector from oxidative and inflammatory stress by enhancing the endogenous antioxidant defence system. **Ratnayake R**, Liu Y, Paul VJ, Luesch H, *Cancer Prev Res (Phila)*. 2013, 6(9): 989-99
 27. Englerin A stimulates PKC θ to inhibit insulin signalling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Sourbier C, Scroggins BT, **Ratnayake R**, Prince TL, Lee S, Lee MJ, Nagy PL, Lee YH, Trepel JB, Beutler JA, Linehan WM, Neckers L. *Cancer Cell*. 2013, 23(2): 228-37.
 28. Flabelliferins A and B, sesterterpenoids from the South Pacific sponge *Carteriospongia flabellifera*. Diyabalanage T, **Ratnayake R**, Bokesch HR, Ransom T, Henrich CJ, Beutler JA, McMahon JB, Gustafson KR, *J Nat Prod*. 2012, 75(8): 1490-4
 29. Chlorinated englerins with selective inhibition of renal cancer cell growth. Akee RK, Ransom T, **Ratnayake R**, McMahon JB, Beutler JA, *J Nat Prod*. 2012, 75(3): 459-63
 30. Grassypeptolides F and G, cyanobacterial peptides from *Lyngbya majuscula*. Popplewell WL, **Ratnayake R**, Wilson JA, Beutler JA, Colburn NH, Henrich CJ, McMahon JB and McKee TC, *J. Nat Prod*. 2011, 74(8): 1686-91
 31. Nothospondin, a new AP-1 inhibitory quassinoid from the Cameroonian plant *Nothospondias staudtii*. Diyabalanage T, **Ratnayake R**, Wilson JA, Henrich CJ, Beutler JA, Colburn NH, McMahon JB, Gustafson KR, *Bioorg Med Chem Lett*. 2011, 21(15): 4397-9
 32. Inhibitors of the Oncogenic Transcription Factor AP-1 from *Podocarpus latifolius* Devkota. KP, **Ratnayake R**, Colburn NH, Wilson JA, Henrich CJ, McMahon JB, and Beutler JA, *J. Nat. Prod*. 2011, 74(3): 374-7
 33. Flavonoids from Eight Tropical Plant Species That Inhibit the Multidrug Resistance Transporter ABCG2. Versiani MA, Diyabalanage T, **Ratnayake R**, Henrich CJ, Bates SE, McMahon JB, and Gustafson KR, *J. Nat. Prod*. 2011, 74(2), 262-6
 34. Grassypeptolides A-C, Cytotoxic Bis-thiazoline Containing Marine Cyclodepsipeptides. Kwan JC, **Ratnayake R**, Abboud KA, Valerie J. Paul VJ and Luesch H, *J. Org.Chem*. 2010, 75(23): 8012-23
 35. Intramolecular Modulation of Serine Protease Inhibitor Activity in a Marine Cyanobacterium with Antifeedant Properties. Matthew S, **Ratnayake R**, Becerro MA, Ritson-Williams R, Paul VJ and Luesch H, *Mar. Drugs* 2010, 8(6): 1803-1816.
 36. Englerin A, a Selective Inhibitor of Renal Cancer Cell Growth, from *Phyllanthus engleri*, **Ratnayake R**, Covell D, Ransom TR and Beutler JA, *Org. Lett.*, 2009, 11(1): 57-60
 37. Acremolides A-D: lipodepsipeptides from an Australian marine derived fungus, *Acremonium* sp. **Ratnayake R**, Lacey E, Tennant S, Gill JH and Capon RJ, *J. Nat. Prod*. 2008, 71(3): 403-408.
 38. Citromycetins and Bilains A-C: New aromatic polyketides and diketopiperazines from Australian marine-derived and terrestrial *Penicillium* spp. Capon RJ, Stewart M, **Ratnayake R**, Lacey E and Gill JH, *J. Nat. Prod*. 2007, 70(11): 1746-1752.
 39. Kibdelones: New Polyketide Anticancer Agents from a Rare Actinomycete Genus, *Kibdelosporangium*, **Ratnayake R**, Lacey E, Tennant S, Gill JH and Capon RJ, *Chem. Eur. J.*; 2007, 13(5): 1610-1619.
 40. Isokibdelones and kibdelonic acids: A Novel Class of Polyketide Anticancer Agents and their biosynthetic precursors, from a rare Actinomycete Genus, *Kibdelosporangium*, **Ratnayake R**, Lacey E, Tennant S, Gill JH and Capon RJ, *Org. Lett*. 2006, 8(23): 5267-5270.
 41. Aspergillazines A-E: novel heterocyclic dipeptides from an Australian strain of *Aspergillus unilateralis*, Capon RJ, **Ratnayake R**, Stewart M, Lacey E, Tennant S, Gill JH, *Org. Biomol. Chem.*, 2005, 3(1): 123-129.

PRESENTATIONS-POSTERS-LECTURES (include local talks UFHCC and FACCA)

1. Marine Cyanobacterial Compound Preferentially Suppresses HIF-1 α Mediated Cancer Cell Viability and Vascularization, **Ranjala Ratnayake**, Sarath P. Gunasekera, Jia Jia Ma, Long H. Dang, Thomas J. Carney, Valerie J. Paul, Hendrik Luesch, *Gordon Research Conference* Ventura, CA, USA February 2020, (Poster)
2. Marine cyanobacterial compound suppresses in vitro and in vivo vascularization via HIF-1 α pathway. **Ranjala Ratnayake**, Sarath P. Gunasekera, Jia Jia Ma, Long H. Dang, Thomas J. Carney, Valerie J. Paul,

- Hendrik Luesch. *International Conference on Pharmacology: Advances in Translational Sciences and Drug Discovery*, Singapore, July 2019 (Poster)
3. Discovery, Total Synthesis and Key Structural Elements for the Immunosuppressive Activity of Cocosolide, a Symmetrical Glycosylated Macrolide Dimer from Marine Cyanobacteria. Gunasekera SP, Li Y, **Ratnayake R**, Luo D, Lo J, Reibenspies JH, Xu Z, Clare-Salzler MJ, Ye T, Paul VJ, Luesch H. *MaNaPro, XV International Symposium on Marine Natural Products*, Brazil, 2016 (Poster)
 4. Isolation, Structure Elucidation and Biological Evaluation of New Tasihalide Analogues from Marine Cyanobacteria. **Ranjala Ratnayake**, Valerie Paul and Hendrik Luesch. *Natural Products & Bioactive Compounds, Gordon Research Conference* Andover, NH, USA August 2016, (Poster)
 5. Englerins, New Guaiane Sesquiterpenoids as Selective Inhibitors of Renal Cancer Cell Growth from *Phyllanthus engleri*, **Ranjala Ratnayake**, Carole Sourbier, David Covell, Tanya Ransom, Kirk R Gustafson, Marston Linehan and John A Beutler, *Proc. American Society of Pharmacognosy, 50th Annual meeting 2009*, Honolulu, Hawaii, USA; O-15. (Presentation)
 6. Natural product inhibitors of ABCG2, Curtis J. Henrich, Robert W. Robey, Kentaro Takada, Heidi R. Bokesch, Susan E. Bates, Suneet Shukla, Suresh V. Ambudkar, Michael Dean, Jennifer A. Wilson, **Ranjala Ratnayake**, Thushara K. Diyabalanage, Karen L. Erickson, Muhammad A. Versianni, Ekaterina I. Goncharova, James B. McMahon, and Kirk R. Gustafson *5th Annual North American ABC Meeting*, NCI Frederick, USA, in September 2008.
 7. Englerins, Novel Inhibitors of Renal Cancer Cell Growth from the Tanzanian Tree *Phyllanthus engleri*, **Ranjala Ratnayake**, David Covell, Tanya Johnson, Kirk R Gustafson and John A Beutler, *Molecular Targets Retreat, Center for Cancer Research/National Cancer Institute*, Symposium held at NIH, Maryland, USA in 2008. (Poster)
 8. Novel Anticancer Compounds from Microorganisms, Invited Speaker at the Faculty of Natural Sciences, The Open University of Sri Lanka February 2007.
 9. Kibdelones and Analogues: New Heterocyclic Polyketide Anticancer Agents from a Rare Actinomycete Genus, *Kibdelosporangium*, **Ranjala Ratnayake**, Ernest Lacey, Shaun Tennant, Jennifer H. Gill and Robert J. Capon: *Proc. American Society of Pharmacognosy, 47th Annual meeting 2006*, Arlington, Washington, USA; O-21 (Student Research Award Lecture)
 10. Novel Polyketide Anticancer Agents from a New Australian Soil Actinomycetes, **Ranjala Ratnayake**, Ernest Lacey, Shaun Tennant, Jennifer H. Gill and Robert J. Capon: *Proc. American Society of Pharmacognosy, 47th Annual meeting 2006*, Arlington, Washington, USA; P-279 (Poster)
 11. A new, natural coumestan from the fruits of *Psoralea corylifolia*, Ajith. M. Abeysekera, R. D. Ajantha R. Gunawardena, **Ranjala Ratnayake**, Robert J. Capon and G. M. Kamal B. Gunaherath, *Chemistry in Sri Lanka*, 2006, **23**(2), 28.
 12. New Metabolites from Australian Marine derived Fungi, Robert J. Capon, Michael Stewart, **Ranjala Ratnayake**, Leith Fremlin, Colin Skene, Richard O'Hair, Ernest Lacey, Shaun Tennant and Jennifer H. Gill, *PacificChem 2005*, Hawaii. (Poster)
 13. Aspergillazines and acremolides, modified dipeptides from two Australian fungi, **Ranjala Ratnayake**, Michael Stewart, Ernest Lacey, Shaun Tennant, Jennifer H. Gill and Robert J. Capon, *Proc. American Society of Pharmacognosy, 46th Annual meeting 2005*, Corvallis, Oregon, USA; O:8, 40. (Presentation)
 14. Novel Heterocyclic Dipeptide Analogues from *Aspergillus unilateralis*, **Ranjala Ratnayake**, Robert J. Capon, Michael Stewart, Ernest Lacey, Shaun Tennant and Jennifer H. Gill, *20th Royal Australian Chemical Institute Organic Chemistry Conference 2004*, Cairns, Australia. (Poster)
 15. Bioactive Metabolites from Australian Terrestrial Microbes, Robert J. Capon, **Ranjala Ratnayake**, Michael Stewart, Ben Clark, Ernest Lacey, Shaun Tennant and Jennifer H. Gill, *19th Royal Australian Chemical Institute Organic Chemistry Conference 2003*, Lorne, Australia. (Poster)